Edition:
United States

Zeria Pharmaceutical Co Ltd (4559.T)

4559.T on Tokyo Stock Exchange

1,779JPY
24 Mar 2017
Change (% chg)

¥11 (+0.62%)
Prev Close
¥1,768
Open
¥1,772
Day's High
¥1,782
Day's Low
¥1,759
Volume
76,800
Avg. Vol
87,679
52-wk High
¥1,874
52-wk Low
¥1,302

Latest Key Developments (Source: Significant Developments)

Zeria Pharmaceutical gets manufacture and marketing approval for Zentacort® Capsules 3mg
Wednesday, 28 Sep 2016 02:15am EDT 

Zeria Pharmaceutical Co Ltd <4559.T> :Says it gets manufacture and marketing approval for Zentacort® Capsules 3mg (Budesonide), as treatment for Crohn's disease.  Full Article

ZERIA PHARMACEUTICAL amends consolidated mid-year and full-year outlook for FY 2016
Wednesday, 28 Oct 2015 12:00am EDT 

ZERIA PHARMACEUTICAL CO LTD:Says the company lowered the consolidated mid-year outlook for revenue to 30,300 million yen from 31,000 million yen for FY ending March 2016.Operating profit forecast increased to 2,100 million yen from 1,600 million yen.Ordinary profit forecast increased to 1,550 million yen from 1,100 million yen.Net profit attributable to parent company's shareholders forecast increased to 1,600 million yen from 1,100 million yen.Earnings per share increased to 30.12 yen from 20.71 yen.Says the company reaffirmed the consolidated full-year outlook for revenue at 65,000 million yen for FY ending March 2016.Operating profit forecast increased to 4,500 million yen from 4,000 million yen.Ordinary profit forecast increased to 4,100 million yen from 3,500 million yen.Net profit attributable to parent company's shareholders forecast increased to 3,300 million yen from 3,000 million yen.Earnings per share increased to 62.13 yen from 56.48 yen.Comments the expected profit increase from Entocort is the main reason for the forecast.  Full Article

ZERIA PHARMACEUTICAL raises consolidated mid-year profit outlook for FY 2016
Wednesday, 5 Aug 2015 03:00am EDT 

ZERIA PHARMACEUTICAL CO LTD:Says the company reaffirms the consolidated mid-year outlook for revenue of 31,000 mln yen, for the fiscal year ending March 2016.Operating profit forecast increased to 1,600 mln yen from 1,500 mln yen.Ordinary profit forecast increased to 1,100 mln yen from 1,000 mln yen.Net profit forecast increased to 1,100 mln yen from 800 mln yen.Earnings per share increased to 20.71 yen from 15.06 yen.Says profit outlook raised due to increased sales of main products and effective use of expenses.  Full Article

ZERIA PHARMACEUTICAL subsidiary signs agreement on right acquisition
Thursday, 9 Jul 2015 02:30am EDT 

ZERIA PHARMACEUTICAL CO LTD:Wholly owned subsidiary Tillotts Pharma AG signed agreement on July 8 (local time), on acquisition of right in entire world exclude in U.S of "Entocort", which is sold by AstraZeneca."Entocort" is treatment agent for inflammatory bowel disease (IBD).Acquisition amount $215 mln or about 26.5 bln yen.  Full Article

ZERIA PHARMACEUTICAL lowers consolidated full-year outlook for FY 2015
Tuesday, 28 Apr 2015 03:00am EDT 

ZERIA PHARMACEUTICAL CO LTD:Says the company lowered the consolidated full-year outlook for the FY ended March 2015.Revenue forecast decreased to 61,000 million yen from 64,000 million yen.Operating profit forecast decreased to 2,650 million yen from 5,000 million yen.Ordinary profit forecast decreased to 2,750 million yen from 5,000 million yen.Net profit forecast decreased to 2,550 million yen from 4,300 million yen.Earnings per share decreased to 48.01 yen from 80.95 yen.Comments that impact of revision of drug prices and increased expenses are the main reasons for the forecast.  Full Article

ZERIA PHARMACEUTICAL to acquire stake in Pharmaceutical Joint Stock Company of February 3rd
Friday, 17 Apr 2015 03:00am EDT 

ZERIA PHARMACEUTICAL CO LTD:To acquire 49 pct stake in Pharmaceutical Joint Stock Company of February 3rd, which is a Vietnam-based company, engaged in manufacture and sale of pharmaceutical and healthy food.  Full Article

More From Around the Web